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ABSTRACT
Objective: To investigate the clinical effects of rituximab
treatment in relation to immunological effects of rituximab
on tissue-derived B lineage cells and repopulation of
circulating B cells.
Methods: A total of 24 patients with rheumatoid arthritis
(RA) were treated with 261000 mg rituximab and
assessed clinically at 4, 12, 18 and 24 weeks using a
44-joint Disease Activity Score (DAS44). Synovial biopsies
were analysed with immunohistochemistry at baseline
and 12 weeks after treatment. Peripheral blood mono-
nuclear cells were analysed by high sensitivity flow
cytometry at all timepoints.
Results: In this study, a cohort of patients was
dichotomised according to those who achieved a low
disease activity score (DAS44,2.4: LoA group) and those
with persistent disease activity (DAS44.2.4: HiA group)
at any time after rituximab treatment. At baseline, the low
activity (LoA) group had significantly lower DAS44 scores
(median 3.33, range 2.84 to 4.23) than the high activity
(HiA) group (median 3.73, range 3.03 to 5.23; p = 0.022)
and significantly less histological inflammation in syno-
vium (median 6.7, range 1 to 15 vs 16.6, range 4 to 22;
p = 0.036). DAS44 scores before and after rituximab
treatment were associated with synovial infiltration of
CD79a+ CD202 B cells, morphologically resembling
plasma cells. Following treatment with rituximab, the LoA
group had significantly reduced repopulation of circulating
pre-switched IgD+ B cells (median 0.044%, range 0.002
to 0.66 vs 0.45%, range 0.07 to 9.47; p = 0.006) and
post-switched CD27+ B cells (median 0.17%, range 0.04
to 0.39 vs 0.67, range 0.08 to 2.05; p = 0.005) compared
to the HiA group.
Conclusion: The present study demonstrated that a low
disease activity state following rituximab was associated
with reduced infiltration of CD79a+ CD202 plasma cells
in synovium and reduced B cell repopulation.
Several studies have demonstrated the safety and
efficacy of rituximab, a chimaeric monoclonal
antibody directed at the CD20 membrane protein
present on B cells, for the treatment of patients
with rheumatoid arthritis (RA) failing tumour
necrosis factor (TNF)-blocking therapy.1–3 The
benefits of B cell depletion in RA and the finding
of disease-specific autoantibodies prior to clinical
manifestations of RA4 5 have renewed interest in
the role of B cells in RA. However, despite the
promising results in clinical trials, the mechanism
through which B cell depletion interferes with
pathological disease processes is still largely unre-
solved. After a single treatment course of two
infusions of 1000 mg rituximab, B cells are
reportedly depleted for 6–8 months from periph-
eral blood.6 However, when B cells return after
rituximab treatment the clinical course of patients
is unpredictable, as some patients experience
worsening of disease symptoms whereas others
show a prolonged response independent of the
reappearance of B cells in the circulation.7 A recent
report on 24 patients with RA showed that 11
(46%) patients experienced a relapse at the time of
B cell return while 13 (54%) patients had a long-
lasting response after rituximab treatment despite
B cell return.8 Explanations for these as yet
unexplained results involving rituximab treatment
may be derived from studies investigating tissue
effects in patients with RA treated with rituximab.
In these studies, rituximab led to the depletion of
CD20+ B cells not only in peripheral blood but also
in bone marrow and synovium.9–11 Moreover, the
study from our group demonstrated that high
pretreatment expression of B cell markers in
synovium predicted non-responsiveness to ritux-
imab treatment.9 These data confirmed that tissue-
derived B cells are likely to be important to
understand the pathological role of B cells in RA.
The present study aimed to expand the pre-
viously reported results on tissue-derived B cells in
a cohort of rituximab-treated patients with RA,
who failed TNF-blocking therapy. The main goal
of the present study was to dissect the relationship
between clinical and immunological effects of
rituximab treatment on tissue-derived B lineage
cells as well as on repopulating B cells in the
peripheral blood.
PATIENTS AND METHODS
Patients
The present study involved 16 female and 8 male
patients (median age 54 years, range: 34 to 82,
median disease duration 13 years, range 3 to 53)
with severe, erosive RA (median 44-joint Disease
Activity Score (DAS44) at baseline 3.66, range 2.84
to 5.23) who participated in a single-centre, open-
label trial to investigate the clinical and immuno-
logical effects of treatment with rituximab, as
previously described.9 An additional patient was
excluded from the current analysis because the
DAS44 at baseline was lower than 2.4 and
consequently the clinical effects of rituximab
treatment too marginal. All patients had failed
treatment with combination(s) of disease-modify-
ing antirheumatic drugs (DMARDs) and TNF-
blocking agents. Patients were treated with
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rituximab administered as 1000 mg intravenous infusion on
days 1 and 15. As premedication, 100 mg methylprednisolone
and 2 mg clemastine were administered intravenously and
1000 mg acetaminophen orally. TNF-blocking agents were
discontinued with a wash-out period of 8 weeks, whereas
DMARDs were continued at the same dosage (methotrexate
2.5–25 mg/week in 21 patients, prednisolone 5–20 mg/day in 9
patients and leflunomide 20 mg/day in 1 patient). The follow-
up was 24 weeks. The study was approved by the Ethics
Committee of the Leiden University Medical Center and all
patients provided written informed consent.
Clinical effectiveness
Clinical effectiveness was assessed by DAS44, performed by a
single research nurse.12 Patients with high disease activity vs low
disease activity were identified using a cut-off for the DAS44 of
2.4, equal to the cut-off for high vs low disease activity
according to the European League Against Rheumatism
(EULAR) response criteria.13 Patients who achieved a low
disease activity (LoA) at any time in 24 weeks after rituximab
treatment were compared to patients with persistent high
disease activity (HiA) after rituximab treatment. The median
time to achieving the lowest DAS44 was 18 weeks (range 4 to
24) in the LoA group and 18 weeks (range 12 to 24) in the HiA
group (p = 0.75).
Sample collection
Heparinised blood samples were obtained at baseline and at 4,
12 and 24 weeks, and when possible also at 18 weeks, after
initiation of B cell depleting therapy. Bone marrow aspirates
were obtained at baseline. Peripheral blood mononuclear cells
(MNCs) and bone marrow mononuclear cells (BMMCs) were
isolated by density gradient centrifugation over Ficoll-amido-
trizoaat (LUMC, Leiden, The Netherlands).
Arthroscopy, synovial tissue sampling and immunohistochemical
analysis
Arthroscopy of clinically affected knees was performed at
baseline in all patients as previously described14 and the
procedure was repeated at 12 weeks after the first infusion of
rituximab. Repeat biopsies at 3 months were obtained from the
same knee, unless it had been previously injected with
prednisolone in which case the contralateral knee was taken.
At each occasion, 16 to 20 pieces of synovial tissue were
collected using 2.0 mm grasping forceps (Storz, Tuttlingen,
Germany) and embedded in paraffin until analysis.
Immunohistochemical methods and analysis were performed
as previously described.9 Interobserver Pearson correlation
coefficients were 0.97 for CD20cy, 0.94 for CD79a, 0.80 for
CD68, 0.91 for Ki-67, 0.89 for CD138 and 0.92 for CD3 (all
p values,0.001).
High sensitivity flow cytometric analysis
Up to 56105 freshly isolated MNCs were immediately stained
by incubating with mouse anti-human monoclonal antibodies
(mAbs) in phosphate-buffered saline (PBS)/1,0% bovine serum
albumin (BSA) at 4uC for 30 min and analysed by flow
cytometry. To increase the sensitivity of our analysis,15
236105 to 36105 events were collected and analysed whereby
0.05% (lymphogate) corresponded to 55 (7) (mean (SD)) events
(or approximately 1.566106 cells/litre), with zero events in
isotype controls. The following mAbs were used and titrated to
determine the optimal concentration: anti-CD20 fluorescein
isothiocyanate (FITC) (clone 2H7); anti-CD19 phycoerythrin
(PE) (clone H1B19); anti-CD27 PE (clone L128); anti-CD19
PerCp-Cy5.5 (clone SJ25C1); anti-CD38 PerCp-Cy5.5 (clone
HIT-2); anti-IgD (IAG-2); anti-CD3 allophycocyanin (APC)
(UCHT1); anti-CD4 FITC mAb (clone RPA-T4); anti-CD8 PE
(clone RPA-T4) (all from Becton Dickinson, San Jose, California,
USA). After incubation cells were fixed in 1% paraformaldehyde
(LUMC) and analysed within 24–48 h. All stained cells were
analysed with a FACScalibur (Becton Dickinson) flow cyt-
ometer and the associated software program FlowJo (Tree Star,
Ashland, Oregon, USA) was used to calculate frequencies
within the lymphocyte population. Absolute numbers of
CD3+/CD4+ and CD3+/CD8+ T cells were obtained by adding
TruCount beads (Becton Dickinson) to the stained cells, from
which a multiplication factor was obtained for individual
patients at separate timepoints, in order to calculate the
absolute number of B cells and its subsets. B cells were defined
as CD3-/CD19+ cells, the pre-switched, naı¨ve subset as CD3-/
CD19+/IgD+ (referred to as ‘‘naı¨ve B cells’’) and the post-
switched, memory subsets as CD3-/CD19+/CD27+ (referred to
as ‘‘memory B cells’’).
Statistical analysis
Non-parametric Mann–Whitney U tests were used to compare
variables (DAS44 scores, percentages of B cells and scores of
cellular infiltration in synovium) between two groups of
patients with RA, HiA vs LoA groups. Univariate linear
regression analysis was used to correlate the ratio of naive and
memory B cells with the percentage of CD19+ B cells. All
analyses were confirmed using 28-joint DAS (DAS28) scores,
which did not change the results reported. p Values were
considered significant when p(0.05.
RESULTS
Patients with a low B cell load in synovium achieve low disease
activity after a single course of rituximab
We compared the baseline characteristics between patients who
achieved a low disease activity (LoA group: DAS44,2.4)
13 and
those who still had a high disease activity (HiA group:
DAS44.2.4)
13 after rituximab treatment.
As shown in table 1, both groups were comparable with
respect to age, sex distribution and disease duration. However,
the LoA group had significantly lower DAS44 scores (median
3.33, range 2.84 to 4.23) than the HiA group (median 3.73, range
3.03 to 5.23; p = 0.022) at baseline. Moreover, the LoA group
had significantly lower infiltration of CD20+ (median 0, range 0
to 3 vs 2.5, range 0 to 4; p = 0.005), CD79a+ (median 0.67, range
0 to 2 vs 2.5, range 0.33 to 4; p = 0.004), CD138+ (median 0,
range 0 to 2 vs 2.5, range 0 to 4; p = 0.011), CD3+ (median 1,
range 0 to 4 vs 3.5, range 1 to 4; p = 0.029) and Ki-67+ cells
(median 0, range 0 to 3 vs 3, range 0 to 4; p = 0.016).
Additionally, the overall inflammation score in synovium was
significantly lower in the LoA group (median 6.7, range 1 to 15
vs 16.6, range 4 to 22; p = 0.036). Interestingly, the LoA group
was not different from the HiA group with respect to the
proportions of CD19+ B cells in peripheral blood and bone
marrow, including pre-switched (IgD+) or post-switched
(CD27+) subsets (table 1). Although proportions of B cells from
the total lymphocyte population are better comparable between
peripheral blood and bone marrow, absolute numbers of B cells
and their subsets were also calculated and showed no significant
differences (table 1). These data extended our previous
observation that rituximab was particularly effective in patients
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with low DAS44 scores and low synovial inflammation at
baseline.
Disease activity after rituximab treatment is associated with
CD79a+ CD202 plasma cells in synovium
To expand the baseline findings, we compared synovial tissue
infiltrates between patients in the LoA group and HiA group
after rituximab treatment. We found that only CD79a+ residual
B cells, the majority being CD20-, were significantly lower in
the LoA group (median 0.33, range 0 to 1.33) compared to the
HiA group (median 1.33, range 1 to 4; p = 0.016) (table 2). A
trend to significance was observed for infiltrating CD3+ T cells
(median 2, range 1 to 4 vs 4, range 2 to 4; p = 0.06).
Importantly, we noticed that the residual CD79a+cells in
synovium showed a typical morphology of plasma cells, with a
large nucleus, an expanded Golgi system resulting in a
perinuclear halo and an expansion of cytoplasm (fig 1).
In addition, despite significant baseline differences between
the LoA and HiA groups, there was no difference in the
infiltration of CD138+ plasma cells after rituximab treatment
(both median 0, range 0 to 3; p = 0.91). However, we did find a
significant and strong correlation between the reduction of
CD138+ plasma cells and the reduction of CD3+ T cells after
rituximab (r = 0.62; p = 0.014). Taken together, these data
indicated that synovial infiltration of CD79a+ CD202 plasma
cells was related to disease activity before and after rituximab
treatment.
Low disease activity after rituximab treatment is associated
with reduced B cell repopulation
Because of the apparently pivotal role of synovial infiltration of
CD79a+CD202 plasma cells, we hypothesised that the persis-
tence of CD79a+plasma cells in the HiA group was due to
increased differentiation and proliferation of B cells. To test the
latter hypothesis, we examined the repopulation of B cell
subsets in peripheral blood after rituximab expecting increased
B cell levels in patients of the HiA group. By using high
sensitivity flow cytometry, we observed that the frequencies of
repopulating CD19+ B cells correlated strongly with the ratio
between pre-switched (IgD+) B cells and post-switched
(CD27+) B cells (r = 0.66; p,0.001) (fig 2). These data indicated
that early after rituximab-mediated B cell depletion the
repopulation of circulating B cells was dominated by post-
switched (CD27+) B cells and thereafter surpassed by recon-
stitution of pre-switched (IgD+) B cells.
In addition, we observed that at 24 weeks after rituximab
treatment the LoA group had significantly lower pre-switched
(IgD+) B cells (median 0.044%, range 0.002 to 0.66) as well as
post-switched (CD27+) B cells (median 0.17%, range 0.04 to
0.39) in the peripheral blood as compared to the HiA group
Table 1 Baseline characteristics of patients who achieved low disease activity (LoA group; 44-joint Disease
Activity Score (DAS44),2.4) after rituximab treatment, or did not (high activity (HiA) group: DAS44>2.4)
LoA group (n = 11) HiA group (n = 13) p Value
Demographic characteristics:
Age (years) 55 (34 to 82) 49 (39 to 65) 0.17
Female sex (%) 4 (36%) 2 (15%) 0.14
Disease duration (years) 14 (3 to 53) 9 (1 to 32) 0.40
Clinical characteristics:
DAS44 score 3.33 (2.84 to 4.23) 3.73 (3.03 to 5.23) 0.022
Tender joints 9 (6 to 14) 11 (6 to 21) 0.38
Swollen joints 3 (1 to 6) 8 (3 to 20) 0.002
CRP (mg/litre) 27 (2 to 94) 29 (2 to 97) 0.82
BSE (mm/h) 32 (18 to 109) 50 (4 to 114) 0.09
VAS well-being* 52 (24 to 91) 49 (16 to 85) 0.90
Flow cytometry peripheral blood:
CD19+ (%){ 5.30 (1.93 to 14.9) 9.27 (2.03 to 18.4) 0.22
(cells/litre){ 146 (20 to 494) 269 (33 to 657) 0.55
CD19+IgD+ (%){ 4.15 (0.60 to 8.28) 4.57 (1.52 to 15.4) 0.39
(cells/litre) { 97 (6 to 379) 165 (27 to 339) 0.69
CD19+CD27+ (%){ 2.20 (0.71 to 4.55) 2.36 (0.33 to 6.13) 0.35
(cells/litre){ 53 (7 to 245) 64 (5 to 302) 0.74
Flow cytometry bone marrow:
CD19+ (%){ 7.80 (2.90 to 13.5) 7.33 (2.03 to 24.9) 0.86
CD19+IgD+ (%){ 5.77 (0.61 to 10.9) 5.09 (0.70 to 21.2) 0.78
CD19+CD27+ (%){ 2.09 (0.88 to 3.67) 2.11 (0.61 to 5.57) 0.83
Histology synovium:
CD20+ 0 (0 to 3) 2.5 (0 to 4) 0.005
CD79a+ 0.67 (0 to 2) 2.5 (0.33 to 4) 0.004
CD138+ 0 (0 to 2) 2.5 (0 to 4) 0.011
CD68+ 2.5 (1 to 4) 4 (1 to 4) 0.065
CD3+ 1 (0 to 4) 3.5 (1 to 4) 0.029
Ki-67+ 0 (0 to 3) 3 (0 to 4) 0.016
Lining hyperplasia 1.9 (1 to 3) 1.9 (1 to 3) 0.65
Overall inflammation 6.7 (1 to 15) 16.6 (4 to 22) 0.036
Values depicted are median (range). Bold type indicates significant result.
*VAS for well-being subjectively scored by the patient; {percentages are analysed within the lymphocyte gate; {to allow
comparison of results between all compartments, the percentages of circulating B cells are shown.
BSE, blood sedimentation; CRP, C-reactive protein; VAS, visual analogue scale.
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(0.45%, range 0.07 to 9.47 and 0.67, range 0.08 to 2.05,
respectively; p = 0.006 and p = 0.005, respectively) (fig 3).
Accordingly, at 24 weeks the LoA group had significantly fewer
circulating B cells (median 0.25%, range 0.08 to 1.10) than the
HiA group (1.08%, range 0.13 to 9.32; p = 0.013). Importantly,
no significant differences in circulating B cells of its subsets were
found at 4 weeks shortly after rituximab treatment. Altogether,
these data support the hypothesis that achieving low disease
activity after rituximab treatment was associated with reduced
repopulation of B cells and its subsets, indicative of decreased
B cell proliferation and differentiation.
DISCUSSION
The aim of the present study was to investigate the relationship
between clinical effects of rituximab treatment in relation to
immunological effects of rituximab on tissue-derived B lineage
cells as well as repopulating B cells in the peripheral blood. We
observed that attaining a low disease activity following
rituximab treatment (LoA group) was associated with reduced
synovial infiltration of CD79a+ CD202 plasma cells. Moreover,
a significantly slower repopulation of B cells was observed in
patients of the LoA group, indicating reduced B cell prolifera-
tion. Collectively, the present study demonstrated that ritux-
imab led to low disease activity in patients who had reduced
B cell proliferation together with reduced infiltration of early
plasma cells in synovium.
The present study extended previously published data on the
predictive value of synovial B cell load and clinical response to
rituximab treatment in RA.9 Although it seemed counter-
intuitive that B cell depleting therapy was the least effective in
patients with RA with the highest load of synovial B cells, the
Table 2 Semiquantitative scores of cellular infiltration in synovial
specimens from patients with rheumatoid arthritis (RA) 12 weeks after
treatment with rituximab. Patients were dichotomised in two groups:
those who achieved low disease activity (LoA; 44-joint Disease Activity
Score (DAS44),2.4) after rituximab treatment, and those who did not
(high activity (HiA) group; DAS44>2.4)
Post treatment LoA group (n = 11)
HiA group
(n = 13) p Value
CD20+ 0 (0 to 1)* 0 (0 to 3)* 0.93
CD79a+ 0.33 (0 to 1.33) 1.33 (1 to 4) 0.016
CD138+ 0 (0 to 3) 0 (0 to 3) 0.91
CD68+ 2 (2 to 4) 4 (1 to 4) 0.43
CD3+ 2 (1 to 4) 4 (2 to 4) 0.06
Ki-67+ 1 (0 to 3) 2 (0 to 4) 0.23
Lining hyperplasia 1.67 (1 to 3) 1.83 (1 to 3) 0.79
Overall inflammation 7.17 (0 to 17) 12.8 (7 to 20) 0.06
Values depicted are median (range). Bold type indicates significant result.
*All patients were negative for CD20cy staining, except for one patient in each group.
Figure 1 Residual CD79a+B cells after
rituximab have a plasma cell morphology.
The left panels show haematoxylin and
eosin (H&E) staining of plasma cells in
synovium of two different patients 12
weeks after rituximab. Typical
morphology of plasma cells can be
observed: large nucleus compared to
surrounding lymphocytes, an expanded
Golgi system resulting in a perinuclear
halo and an expanded cytoplasm
compared to lymphocytes. The middle
panels show the morphology of
CD79a+cells typically resembling plasma
cells in two patients. For comparison, the
right panels show the morphology of
CD3+ T lymphocytes in two patients.
Figure 2 Repopulation of post-switched B cells in peripheral blood
precedes reconstitution of pre-switched B cells. The ratio of pre-
switched (IgD+) B cells over post-switched (CD27+) B cells correlated
with the total percentage of circulating B cells before and after rituximab
treatment. To determine the dominant phenotype of B cells a ratio of
CD19+ IgD+ (naı¨ve) B cells over CD19+ CD27+ (memory) B cells was
calculated with a ratio.1.0 indicating a predominance of CD19+IgD+
pre-switched B cells and a ratio,1.0 a predominance of CD19+CD27+
post-switched B cells. Each colour of dots represents a different
timepoint during the study.
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present study demonstrated that the presence of CD79a+
plasma cells in synovium was strongly associated with disease
activity after rituximab treatment. Moreover, the finding that
B cell repopulation was significantly reduced in patients
achieving a low disease activity following rituximab treatment
(LoA group), suggested that proliferating, and thus differentiat-
ing,16 17 B cells into plasma cells were actively involved in the
disease process. Of note, we found similar but less significant
results for the association between CD79a+ cells and DAS44 area
under the curve, as a measure of overall inflammation.
Previously, no correlations were reported between changes in
disease activity and (changes in) proportions of B cells in blood,
bone marrow or synovium,9 nor did we observe a significant
association at the 12 weeks timepoint between B cells in blood
bone marrow or synovium.
Previous studies have shown that CD79a is expressed in B cell
lineage from pre-B cell stage up to the plasma cell stage18 19 in
contrast to CD138 which is only expressed on terminally
differentiated plasma cells. Additionally, we previously found a
strong and significant correlation between anti-citrullinated
protein antibody (ACPA)/IgM serum levels and CD79a+
synovial expression.9 So, even though double stainings with
CD79a and CD138 were lacking in this study, it is conceivable
that CD79a+ CD1382 plasma cells are a distinct subset of
plasma cells, as previously observed in patients with multiple
myelomas.20 21 This could explain why CD79a+ and CD138+
plasma cells behaved differently after rituximab treatment: a
T cell-dependent reduction of CD138+ plasma cells was
observed, which was not directly related to disease activity.
Most likely, the latter is best explained by a contact-dependent
interaction between T cells and the survival of long-lived plasma
cells in humans, which was recently described.22 Taken together,
these findings indicate that that the synovial load of
CD79a+plasma cells plays a more pivotal role in disease activity
in patients with RA before and after treatment than CD138+
plasma cells.
The present study demonstrated that effective interference
with B cell proliferation and autoreactive plasma cell formation
in synovium was the most likely mechanism through which
rituximab reduced disease activity in RA. However, due to the
observational design, this study could not completely exclude
other possible mechanisms. The LoA group already had
significantly lower DAS44 scores at baseline, introducing a
possible bias. However, a spin-off of the REFLEX (Randomised
Evaluation oF Long-term Efficacy of Rituximab in RA) study, a
large double-blind, randomised prospective study, has already
reported that the outcome of retreatment with rituximab
improved if disease activity was not allowed to worsen before
retreatment.23 It was found that for every 1.0 point that the
DAS28 was allowed to worsen resulted in a mean (SD) 0.32
(0.04) higher DAS28 score after a subsequent course of
rituximab. These data confirmed that treatment with rituximab
was more effective when disease relapse was not full blown and
rituximab more effectively interfered with the pathogenic
mechanisms underpinning disease relapse. Intriguingly, it was
previously demonstrated that synovium of patients with
advanced RA contained more pronounced plasma cell infiltra-
tion than of patients with early disease.24 Therefore, it is
probable that the low DAS score in our study was not a bias but
part of the plasma cell-associated pathology found in our
patients with RA. Additionally, this study did not address the
reduction of other cell types by rituximab treatment, in line
with a previous report suggesting that B cells orchestrate
synovial cellular infiltration.10 However, the effects of rituximab
on non-B cell infiltrates cannot explain the counterintuitive
finding that less B cell infiltration was associated with a better
response. If anything, the contrary would be expected. Last but
not least, the possibility remained that rituximab was unable to
reduce disease activity in the HiA group due to residual B cells
located at protective sites, such as the peritoneal cavity.25
Although our early repopulation data supported the hypothesis
Figure 3 Repopulation of B cells after rituximab treatment in patients
who achieved low disease activity (LoA group) and patients who did not
(high activity (HiA) group). Percentages of repopulating CD19+ B cells,
CD19+ IgD+ pre-switched B cells and CD19+ CD27+ post-switched B
cells after rituximab treatment. Open symbols represent patients in the
LoA group, closed symbols represent patients in the HiA group. A 2log
scale was used for the y axis to optimise graphic representation.
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of residual, post-switched B cells, these ‘‘resistant’’ B cells could
not explain the increased reconstitution of pre-switched B cells.
Therefore, the effective interference of rituximab with B cell
proliferation and differentiation towards plasma cells was the
most likely mechanism of action explaining the comprehensive
observational data of peripheral blood, bone marrow and
synovium of rituximab-treated patients.
A limitation of our study was the extent of B cell subtyping,
which did not allow identification of IgD+CD27+ unswitched
memory B cells. This subset was estimated to comprise 5% to
15% of the total B cell population.26 However their relevance to
autoimmune diseases remains unclear to date. Additionally, the
use of corticosteroids in our treatment protocol might have
influenced the effects of rituximab on different cell populations
including plasma cells.27 However, in the present study both
groups were treated similarly and therefore comparability was
preserved. Finally, the clinical relevance of the present study
suggesting that rituximab is most effective in patients who did
not yet have high proportions of CD79a+ plasma cells
infiltrating inflamed synovium remains speculative. It was
previously shown that rituximab did not directly deplete tissue-
derived CD79a+ cells.28 Therefore, it is tempting to speculate
that rituximab will be most effective in early RA rather than in
longstanding RA, however, it is clear that replication of these
data is needed in other cohorts.
In conclusion, the present study demonstrated that the
effective reduction of disease activity by rituximab in patients
with RA could be explained by the presence of CD79a+ plasma
cells in synovium and that low disease activity associated with
fewer CD79a+ plasma cells and a reduction of B cell prolifera-
tion. Future studies will need to confirm whether B cell
proliferation and plasma cell formation have a pivotal role in
RA pathogenesis.
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